Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GUCY1B2 | O75343 | 15/20 | 0.47 |
| ▸ | GUCY1A2 | P33402 | 15/20 | 0.47 |
| ▸ | GUCY1A1 | Q02108 | 15/20 | 0.47 |
| ▸ | GUCY1B1 | Q02153 | 15/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29592784 | 0.84 | ALDH1A1 (0.43) | KMT2AALDH1A1SMN1; SMN2GUCY1B2GUCY1A2 | |
| SCHEMBL3551654 | 0.84 | ALDH1A1 (0.67) | KMT2AALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL6351874 | 0.81 | KMT2A (0.56) | KMT2AALDH1A1SMN1; SMN2GUCY1B2GUCY1A2 | |
| SCHEMBL14231688 | 0.81 | GUCY1B2 (0.73) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL24857397 | 0.80 | KMT2A (0.55) | KMT2AALDH1A1SMN1; SMN2GUCY1B2GUCY1A2 | |
| SCHEMBL7978626 | 0.79 | KMT2A (0.54) | KMT2AALDH1A1SMN1; SMN2GUCY1B2GUCY1A2 | |
| SCHEMBL7977505 | 0.78 | TDP1 (0.49) | KMT2AALDH1A1SMN1; SMN2GUCY1B2GUCY1A2 | |
| SCHEMBL2420946 | 0.76 | KDM4E (0.54) | SMN1; SMN2GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL22152346 | 0.76 | ATP4A (0.51) | ALDH1A1SMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL17018449 | 0.76 | SMN1; SMN2 (0.56) | KMT2AALDH1A1SMN1; SMN2GUCY1B2GUCY1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | KMT2A 216/4885ALDH1A1 2855/4885SMN1; SMN2 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.